The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

SUMMARY β-Lactam antibiotics have been widely used as therapeutic agents for the past
70 years, resulting in emergence of an abundance of β-lactam-inactivating β-lactamases …

The β-lactams retain a central place in the antibacterial armamentarium. In Gram-negative
bacteria, β-lactamase enzymes that hydrolyze the amide bond of the four-membered β …

First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have
encountered a worldwide success, particularly in K. pneumoniae isolates. These beta …

Antimicrobial resistance has become one of the greatest threats to public health, with rising
resistance to carbapenems being a particular concern due to the lack of effective and safe …

Background A growing body of observational evidence supports the value of ceftazidime-
avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant …

The global emergence of carbapenemase-producing bacteria capable of hydrolyzing the
once effective carbapenem antibiotics is considered a contemporary public health concern …

The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …

Ceftazidime-avibactam (Zavicefta®) is an intravenously administered combination of the
third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase …

Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread
and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained …